Al Sandrock, the top scientist at Biogen who exited last year in a dispute over its controversial Alzheimer’s treatment, has landed a new job as the CEO of Voyager Therapeutics, the company said Tuesday.
Voyager’s appointment of Sandrock as its new CEO is the latest in a series of moves aimed at refocusing the company on a new gene therapy delivery technology, following setbacks with its earlier pipeline.
For Sandrock, accepting the Voyager CEO post is a reset following a long and distinguished career at Biogen that ended in crisis and his ouster. His departure from Biogen last November was characterized by the company as a retirement. But as STAT previously reported, Biogen CEO Michel Vounatsos forced Sandrock out, faulting him for the controversial approval and disastrous rollout of the Alzheimer’s drug Aduhelm.
Create a display name to comment
This name will appear with your comment
